Dysregulation of angiogenic homeostasis in systemic sclerosis

International Journal of Rheumatic Diseases

Volumn 16, Issue 4, 2013, Pages 448-454

  Farouk, Hanan Mohamed ^a   Hamza, Sherine Hosny ^a   El Bakry, Samah A ^a   Youssef, Sahar S ^a   Aly, Iman Mohamed ^a   Moustafa, Afaf A ^a   Assaf, Naglaa Youssef ^a   El Dakrony, Al Hussein M ^b  

^a AIN SHAMS UNIVERSITY   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

Angiogenesis; Endostatin; Skin; Systemic sclerosis; Vascular endothelial growth factor

Indexed keywords

ENDOSTATIN; VASCULOTROPIN;

ADULT; ANGIOGENESIS; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HOMEOSTASIS; HUMAN; HUMAN TISSUE; LUNG FUNCTION TEST; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PUNCH BIOPSY; RODNAN SKIN SCORE; SCORING SYSTEM; SKIN BIOPSY; SKINFOLD THICKNESS; SYSTEMIC SCLEROSIS;

ANGIOGENESIS; ENDOSTATIN; SKIN; SYSTEMIC SCLEROSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR;

ADULT; BIOPSY; CASE-CONTROL STUDIES; DISEASE PROGRESSION; ENDOSTATINS; FEMALE; HOMEOSTASIS; HUMANS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PHYSIOLOGIC; PULMONARY FIBROSIS; RESPIRATORY FUNCTION TESTS; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SKIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84883445183     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/1756-185X.12130     Document Type: Article

References (26)

1. Pattanaik D, Brown M, Postlethwaite AE (2011) Vascular involvement in systemic sclerosis (scleroderma). J Inflamm Res 4, 105-25.
2. Koch AE (2000) The role of angiogenesis in rheumatoid arthritis: recent developments. Ann Rheum Dis 59 (Suppl 1), i65-71.
3. Liakouli V, Cipriani P, Marrelli A, Alvaro S, Ruscitti P, Giacomelli R (2011) Angiogenic cytokines and growth factors in systemic sclerosis. Autoimmun Rev 10 (10), 590-4.
4. Castro SV, Jimenez SA (2010) Biomarkers in systemic sclerosis. Biomark Med 4 (1), 133-47.
5. Ferrara N, Bunting S (1996) Vascular endothelial growth factor, a specific regulator of angiogenesis. Curr Opin Nephrol Hypertens 5 (1), 35-44.
6. Skovseth DK, Veuger MJ, Sorensen DR, De Angelis PM, Haraldsen G (2005) Endostatin dramatically inhibits endothelial cell migration, vascular morphogenesis, and perivascular cell recruitment in vivo. Blood 105 (3), 1044-51.
7. Dziankowska-Bartkowiak B, Waszczykowska E, Dziankowska-Zaboroszczyk E et al. (2006) Decreased ratio of circulatory vascular endothelial growth factor to endostatin in patients with systemic sclerosis-association with pulmonary involvement. Clin Exp Rheumatol 24 (5), 508-13.
8. Distler O, Del Rosso A, Giacomelli R et al. (2002) Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 4 (6), R11.
9. LeRoy EC, Black C, Fleischmajer R et al. (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15 (2), 202-5.
10. Medsger T, Steen V (1996) Classification, prognosis. In: Clements P, Furst D (eds) Systemic Sclerosis, pp 51-79. Williams and Wilkins, Baltimore, MD.
11. Clements P, Lachenbruch P, Siebold J et al. (1995) Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 22 (7), 1281-5.
12. Verrecchia F, Laboureau J, Verola O et al. (2007) Skin involvement in scleroderma-where histological and clinical scores meet. Rheumatology (Oxford) 46 (5), 833-41.
13. Knapp RG, Miler MC (1992) Clinical Epidemiology and Biostatistics. Harwal Publishing Company, Malvern, PA.
14. Dziankowska-Bartkowiak B, Gerlicz-Kowalczuk Z, Waszczykowska E (2011) Angiogenin and SDF-1alpha serum concentration in patients with systemic sclerosis in relation to clinical status. Arch Med Sci 7 (1), 92-6.
15. Manetti M, Guiducci S, Romano E et al. (2011) Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis. Circ Res 9 (3), e14-26.
16. Carrai V, Miniati I, Guiducci S et al. (2012) Evidence for reduced angiogenesis in bone marrow in SSc: immunohistochemistry and multiparametric computerized imaging analysis. Rheumatology (Oxford) 51 (6), 1042-8.
17. Ma L, Hollenberg MD, Wallace JL (2001) Thrombin-induced platelet endostatin release is blocked by a proteinase activated receptor-4 (PAR4) antagonist. Br J Pharmacol 134 (4), 701-4.
18. Nagashima M, Asano G, Yoshino S (2000) Imbalance in production between vascular endothelial growth factor and endostatin in patients with rheumatoid arthritis. J Rheumatol 27 (10), 2339-42.
19. Soldano S, Montagna P, Brizzolara R, Ferrone C, Parodi A, Cutolo M (2011) Influence of endothelilin-1 receptors antagonists on extracellular matrix prtein synthesis in culture of human scleroderma skin fibroblasts. Ann Rheum Dis 70, A35.
20. Kim YM, Jang JW, Lee OH et al. (2000) Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res 60 (19), 5410-3.
21. Guiducci S, Manetti M, Romano E et al. (2011) Bone marrow-derived mesenchymal stem cells from early diffuse systemic sclerosis exhibit a paracrine machinery and stimulate angiogenesis in vitro. Ann Rheum Dis 70 (11), 2011-21.
22. Distler O, Distler JH, Scheid A et al. (2004) Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 95 (1), 109-16.
23. Galluccio F, Matucci-Cerinic M (2011) Two faces of the same coin: Raynaud phenomenon and digital ulcers in systemic sclerosis. Autoimmun Rev 10 (5), 241-3.
24. Avouac J, Meune C, Ruiz B et al. (2012) Angiogenic biomarkers predict the occurrence of digital ulcers in systemic sclerosis. Ann Rheum Dis 71 (3), 394-9.
25. Distler JH, Gay S, Distler O (2006) Angiogenesis and vasculogenesis in systemic sclerosis. Rheumatology (Oxford) 45 (Suppl 3), iii26-7.
26. De Santis M, Bosello SL, Capoluongo E et al. (2012) A vascular endothelial growth factor deficiency characterises scleroderma lung disease. Ann Rheum Dis 71 (9), 1461-5.